These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Biochemical markers of bone metabolism in growing thoroughbreds: a longitudinal study. Price JS, Jackson BF, Gray JA, Harris PA, Wright IM, Pfeiffer DU, Robins SP, Eastell R, Ricketts SW. Res Vet Sci; 2001 Aug; 71(1):37-44. PubMed ID: 11666146 [Abstract] [Full Text] [Related]
24. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y. J Bone Miner Metab; 2004 Aug; 22(2):127-31. PubMed ID: 14999523 [Abstract] [Full Text] [Related]
25. Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis. Majkić-Singh N, Ilić M, Ignjatović S, Aleksandra-Postić-Grujin. Clin Lab; 2002 Aug; 48(7-8):407-13. PubMed ID: 12146575 [Abstract] [Full Text] [Related]
26. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. Hannon R, Blumsohn A, Naylor K, Eastell R. J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076 [Abstract] [Full Text] [Related]
27. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. Popp AW, Bodmer C, Senn C, Fuchs G, Kraenzlin ME, Wyss H, Birkhaeuser MH, Lippuner K. Maturitas; 2006 Jan 20; 53(2):191-200. PubMed ID: 16368472 [Abstract] [Full Text] [Related]
28. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. Noguchi M, Noda S. J Urol; 2001 Sep 20; 166(3):1106-10. PubMed ID: 11490307 [Abstract] [Full Text] [Related]
29. Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women. García-Pérez MA, Moreno-Mercer J, Tarín JJ, Cano A. Gynecol Endocrinol; 2006 Apr 20; 22(4):179-84. PubMed ID: 16723303 [Abstract] [Full Text] [Related]
30. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP]. Kobayashi Y, Ochi M, Tokue A. Hinyokika Kiyo; 2000 Dec 20; 46(12):869-72. PubMed ID: 11211802 [Abstract] [Full Text] [Related]
31. Effect of calcium fortified milk supplementation with or without vitamin K on biochemical markers of bone turnover in premenopausal women. Kruger MC, Booth CL, Coad J, Schollum LM, Kuhn-Sherlock B, Shearer MJ. Nutrition; 2006 Dec 20; 22(11-12):1120-8. PubMed ID: 17030114 [Abstract] [Full Text] [Related]
32. Bone marker alterations in patients with type 1 Gaucher disease. Ciana G, Martini C, Leopaldi A, Tamaro G, Katouzian F, Ronfani L, Bembi B. Calcif Tissue Int; 2003 Mar 20; 72(3):185-9. PubMed ID: 12522660 [Abstract] [Full Text] [Related]
33. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment. Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J. Rheumatology (Oxford); 2004 Jul 20; 43(7):869-74. PubMed ID: 15054158 [Abstract] [Full Text] [Related]
35. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Bjøro K, Brandsaeter B, Wiencke K, Bjøro T, Godang K, Bollerslev J, Schrumpf E. Scand J Gastroenterol; 2003 Mar 20; 38(3):320-7. PubMed ID: 12737449 [Abstract] [Full Text] [Related]
36. Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover. de Valk-de Roo GW, Netelenbos JC, Peters-Muller IR, Voetberg GA, van de Weijer PH, Bouman AA, Popp-Snijders C, Kenemans P. Maturitas; 1997 Dec 15; 28(2):153-62. PubMed ID: 9522323 [Abstract] [Full Text] [Related]
38. The duration of exercise as a regulator of bone turnover. Karlsson KM, Karlsson C, Ahlborg HG, Valdimarsson O, Ljunghall S. Calcif Tissue Int; 2003 Oct 15; 73(4):350-5. PubMed ID: 12874708 [Abstract] [Full Text] [Related]
39. Effects of a combined estrogen-gestagen regimen on serum levels of the carboxy-terminal propeptide of human type I procollagen in osteoporosis. Hasling C, Eriksen EF, Melkko J, Risteli L, Charles P, Mosekilde L, Risteli J. J Bone Miner Res; 1991 Dec 15; 6(12):1295-300. PubMed ID: 1724340 [Abstract] [Full Text] [Related]
40. [Effect of estrogen replacement therapy on the serum osteocalcin level in the postmenopausal and castrated women]. Honjo S, Mizunuma H, Soda M, Igarashi M. Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct 15; 41(10):1571-6. PubMed ID: 2555424 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]